

Giovanni Triolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12155845/publications.pdf>

Version: 2024-02-01

79
papers

4,398
citations

87886

38
h-index

110368

64
g-index

79
all docs

79
docs citations

79
times ranked

5125
citing authors

#	ARTICLE	IF	CITATIONS
1	Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 686-691.	5.6	340
2	Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1739-1747.	0.9	236
3	Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1123-1132.	0.9	226
4	Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 955-965.	6.7	215
5	Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2003, 48, 728-731.	6.7	206
6	Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1566-1574.	0.9	145
7	Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 295-301.	0.9	143
8	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	3.5	143
9	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	5.5	130
10	Interleukin-22 and interleukin-22-producing Nkp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1869-1878.	6.7	111
11	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, Sjögren's syndrome, systemic sclerosis, and mixed connective tissue disease). <i>Journal of Autoimmunity</i> , 2017, 84, 107-117.	3.8	107
12	IL-34 is overexpressed in the inflamed salivary glands of patients with Sjögren's syndrome and is associated with the local expansion of pro-inflammatory CD14 ^{bright} CD16 ⁺ monocytes. <i>Rheumatology</i> , 2013, 52, 1009-1017.	1.9	92
13	Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 2264-2272.	1.9	83
14	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	2.2	83
15	Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1922-1931.	5.6	80
16	New approaches in the treatment of Adamantiades-Behçet's disease. <i>Current Opinion in Rheumatology</i> , 2006, 18, 3-9.	4.3	79
17	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	3.0	76
18	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 864-872.	2.0	70

#	ARTICLE	IF	CITATIONS
19	One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. <i>Rheumatology International</i> , 2011, 31, 33-37.	3.0	67
20	Ectopic expression of CXCL13, BAFF, APRIL and LT- α is associated with artery tertiary lymphoid organs in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 235-243.	0.9	67
21	Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 1596-1604.	1.9	66
22	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	5.8	65
23	Cognitive impairment in Behçet's disease patients without overt neurological involvement. <i>Journal of the Neurological Sciences</i> , 2004, 220, 99-104.	0.6	62
24	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	3.4	61
25	Subclinical gut inflammation in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 89-96.	4.3	61
26	NF- κ B protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. <i>Arthritis and Rheumatism</i> , 2005, 52, 2179-2191.	6.7	59
27	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.9	55
28	Expansion of intestinal CD4 ⁺ CD25 ^{high} Treg cells in patients with ankylosing spondylitis: A putative role for interleukin-10 in preventing intestinal Th17 response. <i>Arthritis and Rheumatism</i> , 2010, 62, 3625-3634.	6.7	53
29	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016, 18, 78.	3.5	52
30	New insights into the pathogenesis of giant cell arteritis. <i>Autoimmunity Reviews</i> , 2017, 16, 675-683.	5.8	51
31	Enhancement of Endothelial Cell E-Selectin Expression by Sera from Patients with Active Behçet's Disease: Moderate Correlation with Anti-endothelial Cell Antibodies and Serum Myeloperoxidase Levels. <i>Clinical Immunology</i> , 1999, 91, 330-337.	3.2	50
32	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	5.8	46
33	IL-1 α at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	3.0	46
34	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	2.0	45
35	Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014, 53, 104-113.	1.9	44
36	Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. <i>Rheumatology</i> , 2010, 49, 2076-2083.	1.9	43

#	ARTICLE	IF	CITATIONS
37	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	1.0	42
38	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. <i>Rheumatology</i> , 2014, 53, 1313-1320.	1.9	41
39	CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity. <i>Arthritis Research and Therapy</i> , 2017, 19, 178.	3.5	41
40	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	5.8	38
41	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1041-1047.	3.0	36
42	V γ 9/V δ 2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. <i>Arthritis Research</i> , 2003, 5, R262.	2.0	35
43	Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. <i>Rheumatology International</i> , 2009, 30, 193-198.	3.0	33
44	Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	2.1	32
45	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31
46	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.9	29
47	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	3.5	29
48	Phenotype and functional changes of V γ 9/V δ 2 T lymphocytes in Behçet's disease and the effect of infliximab on V γ 9/V δ 2 T cell expansion, activation and cytotoxicity. <i>Arthritis Research and Therapy</i> , 2010, 12, R109.	3.5	28
49	IL-17 polarization of MAIT cells is derived from the activation of two different pathways. <i>European Journal of Immunology</i> , 2017, 47, 2002-2003.	2.9	26
50	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 1364-1375.	1.9	26
51	The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 210-214.	0.8	26
52	Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. <i>Rheumatology</i> , 2012, 51, 1966-1972.	1.9	24
53	Intestinal dysbiosis and innate immune responses in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 352-358.	4.3	24
54	The role of the gastrointestinal tract in the pathogenesis of rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 889-900.	3.3	23

#	ARTICLE	IF	CITATIONS
55	Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2018, 45, 630-637.	2.0	23
56	The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 533-541.	3.0	22
57	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
58	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e8180.	1.0	21
59	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.7	19
60	Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1265-1275.	5.6	18
61	Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. <i>Rheumatology</i> , 2014, 53, 1307-1312.	1.9	17
62	Clinical efficacy of $\alpha 4$ integrin block with natalizumab in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2053-2054.	0.9	17
63	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	1.9	15
64	Brief Report: Functional Interaction of Endoplasmic Reticulum Aminopeptidase 2 and HLA-B*27 Activates the Unfolded Protein Response. <i>Arthritis and Rheumatology</i> , 2017, 69, 1009-1015.	5.6	14
65	Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. <i>World Journal of Gastroenterology</i> , 2017, 23, 7139-7149.	3.3	14
66	Motor cortex tRNS improves pain, affective and cognitive impairment in patients with fibromyalgia: preliminary results of a randomised sham-controlled trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 100-105.	0.8	14
67	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. <i>Mechanisms of Ageing and Development</i> , 2016, 159, 44-48.	4.6	13
68	Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 999-1004.	3.4	11
69	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , 2018, 57, vii23-vii31.	1.9	9
70	Cardiovascular Disease in Primary Sjögren's Syndrome. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 164-169.	0.8	8
71	Immune complex-mediated inhibition of lymphocyte Fc- γ 3 receptors in the plasma of patients with type 1 (insulin-dependent) diabetes mellitus: Association with anti-ssDNA antibodies. <i>Clinical Immunology and Immunopathology</i> , 1990, 54, 228-236.	2.0	5
72	Detection of two forms of HBeAg (free and IgG bound HBeAg) in patients with HBe antigenemia using staphylococcus bearing protein A. <i>Liver</i> , 1985, 5, 205-211.	0.1	3

#	ARTICLE	IF	CITATIONS
73	Use of Rituximab in the Management of Sjögren's Syndrome. Current Treatment Options in Rheumatology, 2015, 1, 277-291.	1.4	3
74	Inhibition of Fc γ 3 Receptors in the Plasma of Subjects with Down's Syndrome. Clinical Immunology and Immunopathology, 1993, 69, 92-96.	2.0	2
75	Do Immune Complexes Formed with Autoantibodies Have a Role in the Maintenance of Immune Homeostasis Through Interaction with FC Receptors. Autoimmunity, 2000, 32, 153-160.	2.6	2
76	<i>In vitro</i> synthesis of IgG and IgM in patients with HBsAg positive and HBsAg negative chronic active hepatitis. Liver, 1983, 3, 207-212.	0.1	2
77	Response to: 'Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al. Annals of the Rheumatic Diseases, 2018, 77, e17-e17.	0.9	2
78	Response to: 'IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis' by Neerincx et al.. Annals of the Rheumatic Diseases, 2014, 73, e69-e69.	0.9	1
79	Cell Immunity in Inflammatory Vasculitis. Current Immunology Reviews, 2015, 11, 3-11.	1.2	0